Conversely, dampening c-MET activity has been shown to stabilize PD-L1, enabling tumor cells to evade T cell responses, thereby contributing to the limited success of c-MET inhibitors in clinical trials targeting non-small cell lung cancer (NSCLC) (9). The gene discussed is MET; the disease is neoplasm.